-
Press Release
IR News
Santen Launches TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension
-
Press Release
IR News
Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Diabetic Macular Edema (DME), its Fourth Indication
-
Press Release
IR News
Santen and Singapore Eye Research Institute (SERI) Announce a Collaboration to Develop New Ophthalmic Therapeutics
-
Information
Meeting video on Financial Results of the 2nd Quarter of FY2014
-
Press Release
IR News
Santen Announces Financial Result for the Second Quarter ended September 30, 2014
-
Press Release
IR News
Santen Receives Financing from the Development Bank of Japan based on "DBJ Environmental Rating"
-
Information
Santen to release Annual Report 2014
-
Press Release
IR News
Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck
-
Press Release
IR News
Increase of Capital for a Consolidated Subsidiary in Europe
-
Press Release
IR News
Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Myopic Choroidal Neovascularization (mCNV)
-
Press Release
IR News
Eyestrain Common Issue Caused by Contact Lenses!? Santen Launches Soft Santear Hitomi Stretch, an Eye Drop for Use with Soft Contact Lenses to Reduce Eyestrain by Relaxing Ciliary Muscle Stiffness Which Can Be a Cause of Eyestrain
-
Press Release
IR News
Notice on Details of the Rights to Subscribe for New Shares (Stock Options as Stock-Linked Remuneration)
-
Press Release
IR News
Santen Files for Manufacturing/Marketing Approval of its Glaucoma and Ocular Hypertension Therapeutic, COSOPT Mini Combination Ophthalmic Solution
-
Information
Meeting video on Financial Results of the 1st Quarter of FY2014 and Medium-term management plan for FY2014-2017
-
Press Release
IR News
Santen Announces Financial Result for the First Quarter ended June 30, 2014
-
Press Release
IR News
Santen to Grant Rights to Subscribe for New Shares as Stock Options as Stock-Linked Remuneration
-
Press Release
IR News
Medium-Term Management Plan FY2014-2017
-
Information
Posted new contents "Carrying Ophthalmologists Aspirations"
-
Press Release
IR News
Changes in Significant Shareholders
-
Press Release
IR News
Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck
-
Information
Posted meeting video on the Financial Result of FY2013
-
Press Release
IR News
Santen Announces Financial Results for the Year ended March 31, 2014
-
Press Release
IR News
Notice of the Nominations for the Member of the Board
-
Press Release
IR News
Santen Announces the Signing of Agreement between Merck for the Purchase of Assets in Ophthalmology
-
Press Release
IR News
Santen Phase III Study Meets Primary Endpoint for The treatment of Non-Infectious Posterior Segment Uveitis (NI-PSU)
-
Press Release
IR News
Santen Partners with Akorn, Inc. subsidiary Oak Pharmaceuticals for Marketing of Tafluprost, the Treatment of Glaucoma and Ocular Hypertension in the U.S.
-
Press Release
IR News
The Osaka Study: An epidemiological survey showing that dry eye disease lowers work productivity, affects quality of life and correlates with metabolic syndrome
-
Press Release
IR News
Notice of the appointment of Corporate Officers
-
Press Release
IR News
Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology
-
Press Release
IR News
Changes in Significant Shareholders
-
Press Release
IR News
Revision of consolidated earnings forecasts for FY 2013
-
Press Release
IR News
Santen Announces Financial Result for the Third Quarter ended December 31, 2013
-
Press Release
IR News
Santen Pharmaceutical Voluntarily Adopts International Financial Reporting Standards (IFRS)
